KVUE Kenvue Inc.
Company Analysis
Latest News
Kimberly-Clark Secures Conditional EU Approval for $40 Billion Kenvue Deal
The European Commission has granted conditional antitrust approval for Kimberly-Clark’s $40 billion acquisition of Kenvue, the maker of Tylenol and other...
Kenvue Enters Agreement to Amend Debt Covenants Ahead of Kimberly-Clark Acquisition
Kenvue Inc. entered into a Third Supplemental Indenture on October 9, 2026, to amend the terms of its outstanding series of senior notes. This action is being...
Kimberly-Clark Taps Kenvue Leaders as COO Russ Torres Exits
Kimberly-Clark announced leadership changes that will take effect after its pending acquisition of Kenvue, which is expected to close in the fourth quarter of...
Kimberly-Clark offers EU concessions to seal $40 billion Kenvue merger
Kimberly-Clark submitted formal concessions to the European Union to address antitrust concerns regarding its $40 billion acquisition of Kenvue. The European...
Kimberly-Clark Reportedly Planning Asset Sales to Secure EU Approval for Kenvue Deal
Kimberly-Clark is reportedly preparing to offer concessions, including potential asset sales, to address European Union antitrust concerns regarding its...
Kimberly-Clark’s $49B Kenvue Deal Clears Australia, Pending Brand Divestitures
The Australian Competition and Consumer Commission (ACCC) granted conditional approval for Kimberly-Clark’s acquisition of Kenvue on September 2, 2026. To...
Kimberly-Clark Seeks EU Approval for $40B Kenvue Deal, Targeting Health Market
Kimberly-Clark formally requested antitrust approval from the European Commission for its $40 billion acquisition of Kenvue. The target company manufactures...
Kimberly-Clark’s $49B Kenvue Deal Faces Deeper China Probe, Expert Urges Slowdown
China’s State Administration for Market Regulation (SAMR) escalated its review of Kimberly-Clark’s $49 billion acquisition of Kenvue. The regulator moved the...
Kenvue's second quarter revenue of $3.96 billion misses estimates, though organic sales grew 1.6%.
Kenvue reported second quarter 2026 net sales of $3.96 billion, up 3.0% year-over-year, and adjusted diluted EPS of $0.31, a 7% increase. The results narrowly...
Kenvue Inc. Q2 2026 Earnings Preview: What Analysts Expect on August 06, 2026
Wall Street analysts project Kenvue to report Q2 2026 revenue of $3.97 billion and adjusted EPS of $0.32, with the current stock price of $19.24 sitting just...
J&J proposes $5.5B talc settlement, easing Kenvue liability
Johnson & Johnson proposed a $5.5 billion settlement to resolve approximately 76,000 U.S. lawsuits alleging its talc-based baby powder caused ovarian cancer....
Kenvue Secures FDA Approval for First Tylenol and Naproxen Combination Pill
The U.S. Food and Drug Administration (FDA) approved Kenvue’s new over-the-counter (OTC) medication, Tylenol with Naproxen. This product is the first to...
Kenvue Faces 500+ Revived Tylenol Lawsuits, Court Reinstates Expert Testimony
The 2nd U.S. Circuit Court of Appeals in Manhattan revived more than 500 lawsuits against Kenvue. These claims allege a link between prenatal Tylenol use and...
🟢 Kenvue Inc. is trading 5.01% up today as investors rotate into defensive consumer staples
Kenvue Inc. is trading 5.01% up at $17.73 as investors rotate into defensive consumer staples during a broad risk-off session. • The move comes despite no...
🟢 Kenvue Inc. is trading 4.0% up today on potential defensive rotation
Kenvue Inc. is trading at $17.56 (+4.03%) as the stock shows strength despite a broader market selloff that is pressuring many other equities. • No...
Kenvue's first quarter 2026 adjusted EPS beat estimates, but organic growth of 0.7% was sluggish.
Kenvue reported first quarter 2026 net sales of $3.91 billion, a 4.5% year-over-year increase, and adjusted diluted EPS of $0.32, beating analyst estimates....
Kenvue Inc. Q1 2026 Earnings Preview: What Analysts Expect on May 07, 2026
Kenvue is expected to report Q1 2026 revenue of $3.84 billion and adjusted EPS of $0.27, as the stock trades around $17.44 against an average analyst price...